Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
Frazier Life Sciences XII, L.P. will focus on creating and investing in pioneering companies developing novel therapeutics
Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong support from both longstanding and new limited partners. Consistent with prior FLS venture funds, FLS XII will primarily invest in company creation and early-stage private biopharmaceutical companies.
"We appreciate the continued support of our limited partners, many of whom have been with us since the launch of our first dedicated venture fund in 2016," said Patrick Heron, Managing Partner at Frazier Life Sciences. "With FLS XII, we look forward to continuing to work with exceptional entrepreneurs to advance therapeutic programs with the potential to address significant medical needs."
Frazier Life Sciences has raised over $3.6 billion across five dedicated venture funds since 2016, alongside more than $1.7 billion raised in long-only public funds since 2021.
The FLS team includes seven investment partners and a growing group of over 35 investment professionals, operating professionals, and senior advisors with broad biopharmaceutical experience across therapeutic areas and company stages. The firm takes a hands-on, collaborative approach to company building, leading to 25 new companies launched since 2020. Noteworthy investments include Alpine Immune Sciences (acquired by Vertex), Arcutis Biotherapeutics (NASDAQ:ARQT), Mirum Pharmaceuticals (NASDAQ:MIRM), NewAmsterdam Pharma (NASDAQ:NAMS), Tarsus Pharmaceuticals (NASDAQ:TARS), and Amunix Pharmaceuticals (acquired by Sanofi), among others.
About Frazier Life Sciences
Frazier Life Sciences (FLS) invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Since 2016, the firm has raised over $5.3 billion including venture funds focusing on company creation and private companies and long-only public funds focused on small and mid-cap public companies. Since 2010, FLS portfolio companies have achieved over 65 FDA-approved therapeutics and completed more than 60 IPOs or strategic acquisitions.
FLS is headquartered in Palo Alto, CA, with offices in San Diego, Seattle, and Boston.
For more information, please visit frazierls.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250731285238/en/
For media inquiries, please contact:
Ailsa Dalgliesh, Ph.D.
Head of Investor Relations
ailsa@frazierls.com
